OncLive Staff

Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.

TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.